L-LYSINAMIDE, L-LYSYL-L-LYSYL-L-TRYPTOPHYL-L-TRYPTOPHYL-L-LYSYL-L-LYSYL-L-TRYPTOPHYL-.BETA.-PHENYL-L-PHENYLALANYL-
Triple-Negative Breast Cancer
Lytix Biopharma ASprotein_peptidePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
448 Active assets in the Triple-Negative Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capivasertib AstraZeneca | Phase 3 | BB |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 4 | BB |
Carboplatin M.D. Anderson Cancer Center | Phase 4 | BB |
Veliparib National Cancer Institute (NCI) | Phase 3 | BB |
Atezolizumab European Institute of Oncology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
L-LYSINAMIDE, L-LYSYL-L-LYSYL-L-TRYPTOPHYL-L-TRYPTOPHYL-L-LYSYL-L-LYSYL-L-TRYPTOPHYL-.BETA.-PHENYL-L-PHENYLALANYL- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →